Antares Pharma
- Home ›
- US ›
- Healthcare
Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The last earnings update was 18 days ago. More info.
Add to Portfolio Compare Print
- Antares Pharma has significant price volatility in the past 3 months.
ATRS Share Price and Events
7 Day Returns
1 Year Returns
ATRS Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Antares Pharma (ATRS) | 1.4% | 3.3% | -13% | 11.1% | 235.8% | -6.3% |
| US Medical Equipment | -0.6% | -0.4% | -0.6% | 11.7% | 59.4% | 92.5% |
| US Market | -0.7% | -2% | 2.4% | 3% | 39.2% | 42% |
1 Year Return vs Industry and Market
- ATRS outperformed the Market in United States of America which returned 3% over the past year.
ATRS Value
Is Antares Pharma undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Antares Pharma
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Antares Pharma.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 7 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 8.4% |
| Perpetual Growth Rate | 10-Year US Government Bond Rate | 2.7% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year US Govt Bond Rate | 2.7% |
| Equity Risk Premium | S&P Global | 6% |
| Medical Equipment Unlevered Beta | Simply Wall St/ S&P Global | 0.9 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.896 (1 + (1- 21%) (5.93%)) |
0.958 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
0.96 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.958 * 5.96%) |
8.44% |
Discounted Cash Flow Calculation for NasdaqCM:ATRS using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Antares Pharma is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (USD, Millions) | Source |
Present Value Discounted (@ 8.44%) |
|
|---|---|---|---|
| 2019 | -24.50 | Analyst x1 | -22.59 |
| 2020 | 26.30 | Analyst x1 | 22.37 |
| 2021 | 80.40 | Analyst x1 | 63.05 |
| 2022 | 84.60 | Analyst x1 | 61.18 |
| 2023 | 108.50 | Analyst x1 | 72.36 |
| 2024 | 128.20 | Est @ 18.16% | 78.84 |
| 2025 | 145.55 | Est @ 13.53% | 82.54 |
| 2026 | 160.52 | Est @ 10.29% | 83.95 |
| 2027 | 173.40 | Est @ 8.02% | 83.62 |
| 2028 | 184.56 | Est @ 6.43% | 82.08 |
| Present value of next 10 years cash flows | $607.39 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= $184.56 × (1 + 2.73%) ÷ (8.44% – 2.73%) |
$3,320.20 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= $3,320.20 ÷ (1 + 8.44%)10 |
$1,476.57 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= $607.39 + $1,476.57 |
$2,083.95 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $2,083.95 / 162.62 |
$12.81 |
| Calculation | Result | |
|---|---|---|
| Value per share (USD) | From above. | $12.81 |
| Current discount | Discount to share price of
$2.81
= -1 x ($2.81 - $12.81) / $12.81 |
78.1% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Current Discount
Current Discount Checks
- Antares Pharma's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Antares Pharma's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Antares Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Antares Pharma's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2019-03-31) in USD | $-0.04 |
| NasdaqCM:ATRS Share Price ** | NasdaqCM (2019-05-17) in USD | $2.81 |
| United States of America Medical Equipment Industry PE Ratio | Median Figure of 64 Publicly-Listed Medical Equipment Companies | 38.66x |
| United States of America Market PE Ratio | Median Figure of 3,088 Publicly-Listed Companies | 17.89x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Antares Pharma.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqCM:ATRS Share Price ÷ EPS (both in USD) = 2.81 ÷ -0.04 |
-75.92x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Antares Pharma is loss making, we can't compare its value to the US Medical Equipment industry average.
- Antares Pharma is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does
Antares Pharma's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -75.92x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts |
49.7%per year |
| United States of America Medical Equipment Industry PEG Ratio | Median Figure of 55 Publicly-Listed Medical Equipment Companies | 2.23x |
| United States of America Market PEG Ratio | Median Figure of 2,117 Publicly-Listed Companies | 1.56x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Antares Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Antares Pharma's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2019-03-31) in USD | $0.26 |
| NasdaqCM:ATRS Share Price * | NasdaqCM (2019-05-17) in USD | $2.81 |
| United States of America Medical Equipment Industry PB Ratio | Median Figure of 182 Publicly-Listed Medical Equipment Companies | 4.5x |
| United States of America Market PB Ratio | Median Figure of 5,195 Publicly-Listed Companies | 1.83x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqCM:ATRS Share Price ÷ Book Value per Share (both in USD) = 2.81 ÷ 0.26 |
10.7x |
* Primary Listing of Antares Pharma.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Antares Pharma is overvalued based on assets compared to the US Medical Equipment industry average.
Value checks
We assess Antares Pharma's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check) Antares Pharma has a total score of 2/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
ATRS Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Antares Pharma's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
- Antares Pharma's earnings growth is expected to exceed the United States of America market average.
- Antares Pharma's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NasdaqCM:ATRS Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts | 49.7% |
| NasdaqCM:ATRS Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts | 22.5% |
| United States of America Medical Equipment Industry Earnings Growth Rate | Market Cap Weighted Average | 21.5% |
| United States of America Medical Equipment Industry Revenue Growth Rate | Market Cap Weighted Average | 8.1% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 13.9% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.3% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (1 month ago) | See Below |
| Future Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 259 | 83 | 81 | 3 |
| 2022-12-31 | 227 | 69 | 68 | 4 |
| 2021-12-31 | 195 | 58 | 51 | 5 |
| 2020-12-31 | 169 | 51 | 49 | 7 |
| 2019-12-31 | 102 | 11 | -16 | 6 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2019-03-31 | 74 | -23 | -6 |
| 2018-12-31 | 64 | -17 | -7 |
| 2018-09-30 | 59 | -18 | -16 |
| 2018-06-30 | 56 | -23 | -20 |
| 2018-03-31 | 55 | -25 | -18 |
| 2017-12-31 | 55 | -23 | -17 |
| 2017-09-30 | 55 | -19 | -18 |
| 2017-06-30 | 53 | -17 | -18 |
| 2017-03-31 | 52 | -15 | -21 |
| 2016-12-31 | 52 | -15 | -24 |
| 2016-09-30 | 50 | -14 | -26 |
| 2016-06-30 | 47 | -17 | -26 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (1 month ago) | See Below |
| Future Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
All data from Antares Pharma Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 0.48 | 0.51 | 0.45 | 2.00 |
| 2022-12-31 | 0.40 | 0.46 | 0.36 | 3.00 |
| 2021-12-31 | 0.36 | 0.43 | 0.31 | 3.00 |
| 2020-12-31 | 0.25 | 0.60 | 0.00 | 6.00 |
| 2019-12-31 | -0.10 | -0.06 | -0.13 | 5.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2019-03-31 | -0.04 |
| 2018-12-31 | -0.04 |
| 2018-09-30 | -0.10 |
| 2018-06-30 | -0.13 |
| 2018-03-31 | -0.12 |
| 2017-12-31 | -0.11 |
| 2017-09-30 | -0.11 |
| 2017-06-30 | -0.12 |
| 2017-03-31 | -0.14 |
| 2016-12-31 | -0.16 |
| 2016-09-30 | -0.17 |
| 2016-06-30 | -0.17 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Antares Pharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess Antares Pharma's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Antares Pharma has a total score of 5/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
ATRS Past Performance
How has Antares Pharma performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Antares Pharma does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
- Unable to compare Antares Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Antares Pharma's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
All data from Antares Pharma Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2019-03-31 | 74.14 | -5.86 | 43.46 | 11.82 |
| 2018-12-31 | 63.55 | -6.52 | 36.76 | 12.33 |
| 2018-09-30 | 58.77 | -16.36 | 30.95 | 14.19 |
| 2018-06-30 | 55.96 | -19.88 | 30.81 | 13.87 |
| 2018-03-31 | 55.21 | -18.20 | 32.42 | 11.67 |
| 2017-12-31 | 54.52 | -16.74 | 31.65 | 11.85 |
| 2017-09-30 | 54.67 | -17.53 | 29.17 | 15.11 |
| 2017-06-30 | 53.10 | -18.20 | 26.60 | 17.78 |
| 2017-03-31 | 51.91 | -21.42 | 26.26 | 18.57 |
| 2016-12-31 | 52.22 | -24.34 | 27.93 | 19.59 |
| 2016-09-30 | 49.83 | -26.47 | 26.92 | 21.20 |
| 2016-06-30 | 47.44 | -26.08 | 27.91 | 20.38 |
| 2016-03-31 | 49.63 | -21.53 | 27.50 | 21.00 |
| 2015-12-31 | 45.66 | -20.66 | 26.93 | 19.73 |
| 2015-09-30 | 42.26 | -24.11 | 27.54 | 19.82 |
| 2015-06-30 | 37.74 | -25.55 | 27.74 | 19.11 |
| 2015-03-31 | 29.65 | -33.14 | 30.48 | 18.48 |
| 2014-12-31 | 26.50 | -35.15 | 31.74 | 18.64 |
| 2014-09-30 | 22.84 | -30.71 | 30.99 | 16.38 |
| 2014-06-30 | 21.78 | -29.89 | 28.73 | 16.27 |
| 2014-03-31 | 21.29 | -25.89 | 22.48 | 16.72 |
| 2013-12-31 | 20.62 | -20.51 | 17.01 | 15.26 |
| 2013-09-30 | 21.37 | -19.88 | 13.75 | 17.45 |
| 2013-06-30 | 21.55 | -17.06 | 11.11 | 17.03 |
| 2013-03-31 | 20.24 | -14.76 | 10.32 | 15.12 |
| 2012-12-31 | 22.58 | -11.43 | 9.59 | 14.92 |
| 2012-09-30 | 22.50 | -6.57 | 8.18 | 10.83 |
| 2012-06-30 | 20.73 | -4.33 | 8.21 | 8.36 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Antares Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Antares Pharma has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Antares Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Antares Pharma's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Antares Pharma has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
ATRS Health
How is Antares Pharma's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Antares Pharma's finances.
The net worth of a company is the difference between its assets and liabilities.
- Antares Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Antares Pharma's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- High level of physical assets or inventory.
- Debt is covered by short term assets, assets are 2.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Antares Pharma Company Filings, last reported 1 month ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2019-03-31 | 42.67 | 27.11 | 23.24 |
| 2018-12-31 | 39.00 | 25.13 | 27.89 |
| 2018-09-30 | 24.37 | 25.06 | 28.16 |
| 2018-06-30 | 24.65 | 24.99 | 28.78 |
| 2018-03-31 | 28.25 | 24.93 | 28.11 |
| 2017-12-31 | 33.55 | 24.86 | 31.56 |
| 2017-09-30 | 36.00 | 24.79 | 37.41 |
| 2017-06-30 | 40.28 | 24.72 | 43.38 |
| 2017-03-31 | 41.40 | 0.00 | 23.68 |
| 2016-12-31 | 45.22 | 0.00 | 27.72 |
| 2016-09-30 | 49.04 | 0.00 | 31.78 |
| 2016-06-30 | 54.53 | 0.00 | 36.56 |
| 2016-03-31 | 59.88 | 0.00 | 42.11 |
| 2015-12-31 | 67.04 | 0.00 | 47.91 |
| 2015-09-30 | 72.62 | 0.00 | 47.89 |
| 2015-06-30 | 77.34 | 0.00 | 49.13 |
| 2015-03-31 | 35.15 | 0.00 | 26.54 |
| 2014-12-31 | 41.20 | 0.00 | 40.03 |
| 2014-09-30 | 50.41 | 0.00 | 48.05 |
| 2014-06-30 | 55.44 | 0.00 | 56.02 |
| 2014-03-31 | 63.81 | 0.00 | 60.06 |
| 2013-12-31 | 70.71 | 0.00 | 63.08 |
| 2013-09-30 | 73.87 | 0.00 | 70.01 |
| 2013-06-30 | 79.44 | 0.00 | 69.01 |
| 2013-03-31 | 83.57 | 0.00 | 68.28 |
| 2012-12-31 | 86.55 | 0.00 | 73.21 |
| 2012-09-30 | 35.67 | 0.00 | 30.21 |
| 2012-06-30 | 34.37 | 0.00 | 30.00 |
- Antares Pharma's level of debt (63.5%) compared to net worth is high (greater than 40%).
- The level of debt compared to net worth has increased over the past 5 years (0% vs 63.5% today).
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Antares Pharma has less than a year of cash runway based on current free cash flow.
- Antares Pharma has less than a year of cash runway if free cash flow continues to reduce at historical rates of -0.2% each year.
Financial health checks
We assess Antares Pharma's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Antares Pharma has a total score of 2/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
ATRS Dividends
What is Antares Pharma's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
Antares Pharma
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Antares Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Antares Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
| United States of America Medical Equipment Industry Average Dividend Yield | Market Cap Weighted Average of 24 Stocks | 1.3% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2000 Stocks | 2.5% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.4% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | ||
| 2020-12-31 | ||
| 2019-12-31 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Antares Pharma has not reported any payouts.
- Unable to verify if Antares Pharma's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Antares Pharma's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Antares Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Antares Pharma has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
ATRS Management
CEO
| COMPENSATION | $3,452,880 |
| AGE | 52 |
| TENURE AS CEO | 3.3 years |
CEO Bio
Mr. Robert F. Apple, also known as Bob, has been the Chief Executive Officer and President of Antares Pharma Inc. since January 25, 2016. Mr. Apple served as Chief Operating Officer of Antares Pharma Inc. from September 15, 2014 to January 24, 2016 and served as its Executive Vice President from July 2009 January 24, 2016. He served as the President of the Parenteral Products Division of Antares Pharma Inc. since July 2009 and served as its Chief Financial Officer since February 9, 2006, Chief Accounting Officer and Secretary since February 9, 2006 and also served as its Executive Vice President since 2009. He was responsible for Antares Pharma's financial operations and financial reporting. He served as the Chief Financial Officer of Uman Pharma Inc. He served as Senior Vice President of Antares Pharma Inc. since joined it in February 9, 2006 to July 2009 and served as its Principal Accounting Officer from February 9, 2006 to July 2009. He served as the Chief Operating Officer and Financial Officer of InKine Pharmaceutical Co., Inc. since January 2003 until 2005 and its Chief Financial Officer from 1997 to 2002. He served as an Executive Vice President and Chief Financial Officer of InKine Pharmaceutical Co Inc., from August 2001 to December 2002, Senior Vice President and Chief Financial Officer from November 1998 to July 2001 and Vice President of Finance and Administration from December 1997 to October 1998. Mr. Apple served as Secretary of InKine Pharmaceutical Co., Inc. Prior to InKine Pharmaceutical Co Inc., he was employed by Genaera Corporation, Inc.(formerly, Magainin Pharmaceuticals, Inc.) from July 1995 to 1997, where he served as Corporate Controller. Prior to his eight year tenure at InKine, he held financial roles at several public biotech and technology companies and began his career in public accounting. He served as Corporate Controller of Liberty Technologies, Inc. from May 1994 to July 1995. From August 1988 to May 1994, he was employed by Arthur Andersen and Company LLP, where he held various positions of increasing responsibility. Mr. Apple joined Antares Pharma Inc. in 2006 as Chief Financial Officer and Corporate Secretary. He has been a Director of InKine Pharmaceutical Co. Inc. since July 18, 2003 and Antares Pharma Inc. since March 2016. Mr. Apple is a Certified Public Accountant of AICPA and holds a B.A. degree in accounting from Temple University.
CEO Compensation
- Bob's compensation has been consistent with company performance over the past year.
- Bob's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the Antares Pharma management team in years:
- The tenure for the Antares Pharma management team is about average.
Management Team
Bob Apple
CEO, President & Director
$3M
52
3.3 yrs
Fred Powell
Executive VP & CFO
$1M
57
2.6 yrs
Peter Graham
Executive VP of Human Resources
$1M
51
3.8 yrs
Jim Tursi
EVP, Head of Research & Development & Chief Medical Officer
$745K
53
0.8 yrs
Keith Muckenhirn
Principal Accounting Officer
$361K
55
2.7 yrs
Edward Kessig
Vice President of Sales
2.4 yrs
Peter Sadowski
Senior Vice President of Technology Portfolio & Intellectual Property
$468K
70
Patrick Madsen
Senior Vice President of Operations
Steve Knapp
Senior Vice President of Regulatory Affairs & Quality Assurance
3.2 yrs
Henry Wolfe
Senior Vice President of Product Development
60
2.3 yrs
Board of Directors Tenure
Average tenure and age of the Antares Pharma board of directors in years:
- The tenure for the Antares Pharma board of directors is about average.
Board of Directors
Leonard Jacob
Chairman
$328K
69
10.6 yrs
Bob Apple
CEO, President & Director
$3M
52
3.2 yrs
Thomas Garrity
Independent Director
$183K
69
15.6 yrs
Anton Gueth
Independent Director
$187K
61
15.6 yrs
Marvin Samson
Independent Director
$165K
76
6 yrs
Bob Roche
Independent Director
$167K
62
5.8 yrs
Peter Greenleaf
Director
$35K
48
0.4 yrs
Karen Smith
Director
50
0.2 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 20. Jun 18 | Sell | Jacques Gonella | Individual | 15. Jun 18 | 15. Jun 18 | -565 | $2.95 | $-1,667 | ||
| 13. Jun 18 | Sell | Jacques Gonella | Individual | 11. Jun 18 | 12. Jun 18 | -200,000 | $2.77 | $-546,000 | ||
| 07. Jun 18 | Sell | Jacques Gonella | Individual | 05. Jun 18 | 06. Jun 18 | -43,388 | $2.70 | $-117,148 | ||
| 05. Jun 18 | Sell | Jacques Gonella | Individual | 01. Jun 18 | 05. Jun 18 | -256,612 | $2.70 | $-672,852 | ||
| 01. Jun 18 | Sell | Jacques Gonella | Individual | 01. Jun 18 | 01. Jun 18 | -78,938 | $2.60 | $-205,239 | ||
| 01. Jun 18 | Sell | Jacques Gonella | Individual | 30. May 18 | 30. May 18 | -100,000 | $2.55 | $-255,000 | ||
| 24. May 18 | Sell | Jacques Gonella | Individual | 22. May 18 | 23. May 18 | -200,000 | $2.53 | $-503,000 | ||
Management checks
We assess Antares Pharma's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Antares Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
ATRS News
Simply Wall St News
Antares Pharma, Inc. (NASDAQ:ATRS) Is Expected To Breakeven
Antares Pharma, Inc.'s (NASDAQ:ATRS):. … As path to profitability is the topic on ATRS’s investors mind, I’ve decided to gauge market sentiment. … See our latest analysis for Antares Pharma
Simply Wall St - – Full articleThe Antares Pharma (NASDAQ:ATRS) Share Price Is Up 255% And Shareholders Are Boasting About It
Antares Pharma isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … Antares Pharma's revenue trended up 8.7% each year over three years. … Broadly speaking, this solid progress may well be reflected by the healthy share price gain of 53% per year over three years.
Simply Wall St - – Full articleShould You Worry About Antares Pharma, Inc.'s (NASDAQ:ATRS) CEO Salary Level?
First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Bob Apple's Compensation Compare With Similar Sized Companies. … has a market cap of US$580m, and is paying total annual CEO compensation of US$3.7m.
Simply Wall St - – Full articleHave Insiders Been Selling Antares Pharma, Inc. (NASDAQ:ATRS) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. … So we'll take a look at whether insiders have been buying or selling shares in Antares Pharma, Inc. … As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.'.
Simply Wall St - – Full articleAre Antares Pharma, Inc.'s (NASDAQ:ATRS) Interest Costs Too High?
Help shape the future of investing tools and you could win a $250 gift card! … Investors are always looking for growth in small-cap stocks like Antares Pharma, Inc. … However, an important fact which most ignore is: how financially healthy is the business?
Simply Wall St - – Full articleBefore You Buy Antares Pharma, Inc. (NASDAQ:ATRS), Consider Its Volatility
Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.
Simply Wall St - – Full articleDo Directors Own Antares Pharma, Inc. (NASDAQ:ATRS) Shares?
A look at the shareholders of Antares Pharma, Inc. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … Antares Pharma is a smaller company with a market capitalization of US$424m, so it may still be flying under the radar of many institutional investors.
Simply Wall St - – Full articleHere's What We Think About Antares Pharma Inc's (NASDAQ:ATRS) CEO Pay
This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Bob Apple's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that Antares Pharma Inc has a market cap of US$526m, and is paying total annual CEO compensation of US$3.7m.
Simply Wall St - – Full articleAntares Pharma Inc (NASDAQ:ATRS): Time For A Financial Health Check
Antares Pharma Inc (NASDAQ:ATRS) is a small-cap stock with a market capitalization of US$527m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … Assessing first and foremost the financial health is
Simply Wall St - – Full articleBreaking Down Antares Pharma Inc's (NASDAQ:ATRS) Ownership Structure
Today, I will be analyzing Antares Pharma Inc’s (NASDAQ:ATRS) recent ownership structure, an important but not-so-popular subject among individual investors. … When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … While these are more of a long-term investor’s concern, short-term investors may find the impact of institutional trading overwhelming enough to lose out on what could be a potential opportunity.
Simply Wall St - – Full articleATRS Company Info
Description
Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company’s injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Epinephrine Injection USP for treating Anaphylaxis; Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector EZ II Needle-free Injectors to administer human growth hormone for patients with growth retardation. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; and QuickShot auto injectors. It has strategic alliances with Teva Pharmaceutical Industries, Ltd., AMAG Pharmaceuticals, Inc., and Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.
Details
| Name: | Antares Pharma, Inc. |
| ATRS | |
| Exchange: | NasdaqCM |
| Founded: | 1978 |
| $456,961,668 | |
| 162,619,811 | |
| Website: | http://www.antarespharma.com |
| Address: |
Antares Pharma, Inc. 100 Princeton South, Suite 300, Ewing, New Jersey, 08628, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqCM | ATRS | Common Stock | Nasdaq Capital Market | US | USD | 01. Feb 2001 | |
| DB | MJC | Common Stock | Deutsche Boerse AG | DE | EUR | 01. Feb 2001 |
Number of employees
Current staff
Industry
| Health Care Supplies | |
| Healthcare |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/05/20 01:27 |
| End of day share price update: | 2019/05/17 00:00 |
| Last estimates confirmation: | 2019/05/17 |
| Last earnings filing: | 2019/05/02 |
| Last earnings reported: | 2019/03/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
